Peptide conjugated anti-cancer prodrugs

Details Peptide conjugated anti-cancer prodrugs Peptide conjugated anti-cancer prodrugs

2006-11-02

2009-12-29

Aeder, Sean E (Department: 1642)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

Reexamination Certificate

active

07638127

ABSTRACT:
The present invention relates to pharmaceutical compositions that include a targeting peptide, a protease specific cleavable peptide, and a chemotherapeutic drug that when conjugated are substantially inactive, but upon degradation of the cleavable sequence by a proteolytic enzyme abundant in or within the target cancer cell, the chemotherapeutic drug is released and becomes active, and to methods of use of these compositions for treatment of cancer.

REFERENCES:
patent: 4489065 (1984-12-01), Walton et al.
patent: 5612474 (1997-03-01), Patel
patent: 5795860 (1998-08-01), Witt et al.
patent: 6416758 (2002-07-01), Thorpe et al.
patent: 0 392 745 (1990-10-01), None
patent: 0 859 058 (1998-08-01), None
Freshney (Culture of Animal Cells, A Manual of Basic Technique, Alan R. Liss, Inc., 1983, New York, p. 4).
Dermer (Bio/Technology, 1994, 12:320).
Gura (Science, 1997, 278:1041-1042.).
Ramakrishnan et al (Cancer Research, Mar. 1996, 56: 1324-1330).
Brandner et al (Biochem and Biophys Res Comm, 2006, 340: 836-839).
Robinson et al (J. Cell Sci, Mar. 2001, 114:853-865).
W. Arap et al., “Cancer Treatment by Targeted Drug Delivery to Tumor Vasculature in a Mouse Model,” Science (1998) 279:377-380.
G. Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 1. A Model Study of Structural Requirements for Efficient Release of Doxorubicin,” Bioorganic & Medicinal Chemistry Letters 8 (1998) 3341-3346.
G. Dubowchik et al., “Cathepsin B-Sensitive Dipeptide Prodrugs. 2. Models of Anticancer Drugs Paclitaxel (Taxol®), Mitomycin C and Doxorubicin,” Bioorganic & Medicinal Chemistry Letters 8 (1998) 3347-3352.
Maeda et al., Cancer (1996) 77(5), 858-863.
H. Soyez et al., “The crucial role of spacer groups in macromolecular prodrug design,” Advanced Drug Delivery Reviews 21 (1996) 81-106.
B. Walker et al., “A pore-forming protein with a protease-activated trigger,” Protein Engineering (1994) 7(1):91-97.

Affiliated with

Also associated with

Rating

Peptide conjugated anti-cancer prodrugs does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Peptide conjugated anti-cancer prodrugs, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Peptide conjugated anti-cancer prodrugs will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-4076563